ArteraAI, a San Francisco, CA-based developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, has secured an additional $20 million in funding.   

SaaS Investors 

The round was led by Prosperity7 Ventures and included participation from EDBI, Walden Catalyst Ventures, Wilson Sonsini Goodrich & Rosati, and Trium Ventures, among others.   

Founded in 2019, Prosperity7 Ventures is a corporate venture capital arm of Aramco based in Dhahran, Saudi Arabia. The firm invests in early and growth-stage startups with a long-term view. 

ArteraAI Use of Funds 

The company aims to use the funding to support its international expansion and commercial growth.    

About ArteraAI 

ArteraAI is a precision medicine company that focuses on ushering in the era of precision medicine through AI-driven tests to personalize cancer therapy. ArteraAI offers an AI-enabled test to provide both predictive and prognostic results for patients with localized prostate cancer: ArteraAI Prostate Test. ArteraAI’s multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient’s biopsy and learns from a patient's clinical data. The AI combines this information to predict whether a patient will benefit from a particular therapy and determine their prognosis and has been validated using many Phase 3 randomized trials. 

Funding Details

Company: Artera Inc.    

Raised: $20.0M      

Round: Unknown   

Funding Month: February 2024      

Lead Investors: Prosperity7 Ventures  

Additional Investors: EDBI, Walden Catalyst Ventures, Wilson Sonsini Goodrich & Rosati, and Trium Ventures  

Company Website: https://artera.ai/    

Software Category: AI-enabled Predictive and Prognostic Cancer Tests  

Source: https://www.businesswire.com/news/home/20240201133920/en/